Innovent Biologics has reported a phase 3 victory for IBI343, boosting the prospects of an antibody-drug conjugate (ADC) that Takeda bet big on last year.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Innovent Biologics has reported a phase 3 victory for IBI343, boosting the prospects of an antibody-drug conjugate (ADC) that Takeda bet big on last year.